Últimas noticias sobre Tango Therapeutics (NASDAQ:TNGX) Bolsa

TANGO THERAPEUTICS INC

Tango Therapeutics

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Tango Therapeutics Inc

<p>Reed's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REED#NASDAQ">REED</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-13. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Reed's will report an <strong>earnings per share</strong> (EPS) of $-0.03.</p>
<p>Investors in Reed's are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.12, leading to a 0.0% drop in the share price the following trading session.</p>

<p><img src="https://www.benzinga.com/files/images/story/2025/1747080263_0.png" alt="eps graph" /></p>
<h3>Tracking Reed's's Stock Performance</h3>
<p>Shares of Reed's were trading at $1.755 as of May 09. Over the last 52-week period, shares are up 13.44%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/REED/earnings"><strong>To track all earnings releases for Reed's visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

REED

A Look at Reed's's Upcoming Earnings Report

<p>Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) affirms Q2 sales outlook from $140.00 million-$180.00 million to $140.00 million-$180.00 million vs $132.16 million estimate.</p>


News

Guidance

PLUG

Plug Power Affirms Q2 Sales Guidance of $140.00M-$180.00M vs $132.16M Est

<p>iHeartMedia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IHRT#NASDAQ">IHRT</a>) will report on Q1 2025.</p>


IHRT

iHeartMedia reported Q1 2025 sales of $807.101M

<p>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>), a genomic medicine company, today announced that the first quarter earnings call originally scheduled for 4:30p.m. Eastern on Monday, May 12 will be postponed to 6:30p.m. Eastern on Monday, May 12, 2025.</p>
<p>The registration and access link previously provided remains the same.</p>
<p>Participants should register for, and access, the call using <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fregister-conf.media-server.com%2Fregister%2FBI3ca9a6763be84baaa667afd60ae6be26&amp;esheet=54253241&amp;newsitemid=20250512813982&amp;lan=en-US&amp;anchor=this+link&amp;index=1&amp;md5=b39982dff3f835873e971d688c40c0f5">this link</a>. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.sangamo.com%2Fevents-and-presentations&amp;esheet=54253241&amp;newsitemid=20250512813982&amp;lan=en-US&amp;anchor=Events&amp;index=2&amp;md5=40f3e3a4bd7f7641a69fb21c773d0fe9">Events</a>.</p>
<p>A replay will be available following the conference call, accessible under <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.sangamo.com%2Fevents-and-presentations&amp;esheet=54253241&amp;newsitemid=20250512813982&amp;lan=en-US&amp;anchor=Events&amp;index=3&amp;md5=a7d29744e175a4412cf651198b2c8b08">Events</a>.</p>


SGMO

Sangamo Therapeutics Announces Postponement Of First Quarter 2025 Conference Call To 6:30PM Eastern May12 ,2025

<p>Danaos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAC#NYSE">DAC</a>) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Danaos to report an <strong>earnings per share</strong> (EPS) of $6.55.</p>
<p>Danaos bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.29, leading to a 3.95% increase in the share price the following trading session.</p>
<p>Here's a look at Danaos's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>6.64</td>
<td>6.77</td>
<td>7.27</td>
<td>7.74</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>6.93</td>
<td>6.50</td>
<td>6.78</td>
<td>7.15</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>4.0%</td>
<td>-1.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747080211_0.png" alt="eps graph" /></p>
<h3>Performance of Danaos Shares</h3>
<p>Shares of Danaos were trading at $83.24 as of May 09. Over the last 52-week period, shares are up 3.14%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Opinions on Danaos</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Danaos.</p>
<p>The consensus rating for Danaos is Buy, derived from 1 analyst ratings. An average one-year price target of $105.0 implies a potential 26.14% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of ZIM Integrated Shipping, Star Bulk Carriers and Golden Ocean Group, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Underperform trajectory for ZIM Integrated Shipping, with an average 1-year price target of $13.16, suggesting a potential 84.19% downside.</li>
<li>Analysts currently favor an Buy trajectory for Star Bulk Carriers, with an average 1-year price target of $21.0, suggesting a potential 74.77% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Golden Ocean Group, with an average 1-year price target of $9.0, suggesting a potential 89.19% downside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>In the peer analysis summary, key metrics for ZIM Integrated Shipping, Star Bulk Carriers and Golden Ocean Group are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Danaos</td>
<td>Buy</td>
<td>3.56%</td>
<td>$158.07M</td>
<td>2.66%</td>
</tr>
<tr>
<td>ZIM Integrated Shipping</td>
<td>Underperform</td>
<td>79.84%</td>
<td>$731M</td>
<td>14.10%</td>
</tr>
<tr>
<td>Star Bulk Carriers</td>
<td>Buy</td>
<td>17.25%</td>
<td>$74.11M</td>
<td>1.70%</td>
</tr>
<tr>
<td>Golden Ocean Group</td>
<td>Neutral</td>
<td>-17.01%</td>
<td>$39.56M</td>
<td>2.04%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Danaos ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.</p>
<h3>About Danaos</h3>
<p>Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include, HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia-Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.</p>
<h3>Danaos: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Danaos displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>3.56%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> Danaos's net margin excels beyond industry benchmarks, reaching <strong>35.02%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Danaos's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>2.66%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Danaos's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.1%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.21</strong>, Danaos adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/DAC/earnings"><strong>To track all earnings releases for Danaos visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Peek at Danaos's Future Earnings

<p>Assertio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASRT#NASDAQ">ASRT</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 200 percent decrease over earnings of $0.04 per share from the same period last year.  The company reported quarterly sales of $26.49 million which missed the analyst consensus estimate of $27.52 million by 3.75 percent.  This is a 18.37 percent decrease over sales of $32.45 million the same period last year.</p>


Earnings Beats

Earnings Misses

ASRT

Assertio Holdings Q1 Adj. EPS $(0.04) Beats $(0.06) Estimate, Sales $26.49M Miss $27.52M Estimate

<p>MidCap Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFIC#NASDAQ">MFIC</a>) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.36 by 2.78 percent. This is a 15.91 percent decrease over earnings of $0.44 per share from the same period last year.</p>


MFIC

MidCap Financial Q4 EPS $0.37 Beats $0.36 Estimate

<p>Quanterix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>) lowers FY2025 sales outlook from $140.00 million-$146.00 million to $120.00 million-$130.00 million vs $140.72 million estimate.</p>


QTRX

Quanterix Lowers FY2025 Sales Guidance from $140.00M-$146.00M to $120.00M-$130.00M vs $140.72M Est

HighPeak Energy Q1 Adj. EPS $0.26 Misses $0.29 Estimate, Sales $257.45M Beat $249.18M Estimate

<p>Zevra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-13. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Zevra Therapeutics to report an <strong>earnings per share</strong> (EPS) of $-0.19.</p>
<p>Zevra Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company missed EPS by $0.27, which was followed by a 1.86% drop in the share price the next day.</p>
<p>Here's a look at Zevra Therapeutics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.40</td>
<td>-0.42</td>
<td>-0.44</td>
<td>-0.48</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.67</td>
<td>-0.69</td>
<td>-0.48</td>
<td>-0.40</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>1.0%</td>
<td>3.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747080181_0.png" alt="eps graph" /></p>
<h3>Performance of Zevra Therapeutics Shares</h3>
<p>Shares of Zevra Therapeutics were trading at $7.87 as of May 09. Over the last 52-week period, shares are up 62.19%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Insights on Zevra Therapeutics</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Zevra Therapeutics.</p>
<p>A total of 5 analyst ratings have been received for Zevra Therapeutics, with the consensus rating being Buy. The average one-year price target stands at $22.0, suggesting a potential 179.54% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Tilray Brands, Eton Pharmaceuticals and EyePoint Pharmaceuticals, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Tilray Brands, with an average 1-year price target of $1.0, suggesting a potential 87.29% downside.</li>
<li>Analysts currently favor an Buy trajectory for Eton Pharmaceuticals, with an average 1-year price target of $27.67, suggesting a potential 251.59% upside.</li>
<li>Analysts currently favor an Buy trajectory for EyePoint Pharmaceuticals, with an average 1-year price target of $27.33, suggesting a potential 247.27% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
<p>In the peer analysis summary, key metrics for Tilray Brands, Eton Pharmaceuticals and EyePoint Pharmaceuticals are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zevra Therapeutics</td>
<td>Buy</td>
<td>-6.79%</td>
<td>$10.68M</td>
<td>-65.31%</td>
</tr>
<tr>
<td>Tilray Brands</td>
<td>Neutral</td>
<td>-1.36%</td>
<td>$52.01M</td>
<td>-25.45%</td>
</tr>
<tr>
<td>Eton Pharmaceuticals</td>
<td>Buy</td>
<td>59.26%</td>
<td>$6.48M</td>
<td>-2.96%</td>
</tr>
<tr>
<td>EyePoint Pharmaceuticals</td>
<td>Buy</td>
<td>-17.39%</td>
<td>$10.77M</td>
<td>-14.91%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Zevra Therapeutics ranks at the bottom for Revenue Growth and Gross Profit, indicating lower performance in these areas compared to its peers. However, it ranks at the top for Return on Equity, suggesting a relatively stronger financial position in terms of profitability. Overall, Zevra Therapeutics shows mixed performance when compared to its peers in the analysis.</p>
<h3>All You Need to Know About Zevra Therapeutics</h3>
<p>Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.</p>
<h3>Financial Milestones: Zevra Therapeutics's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Zevra Therapeutics faced challenges, resulting in a decline of approximately <strong>-6.79%</strong> in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Zevra Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-296.76%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-65.31%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-19.34%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.52</strong>.</p>
<p><a href="https://www.benzinga.com/quote/ZVRA/earnings"><strong>To track all earnings releases for Zevra Therapeutics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ZVRA

Zevra Therapeutics's Earnings Outlook

<p>Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) reported quarterly earnings of $2.75 per share which beat the analyst consensus estimate of $(0.16) by 1818.75 percent. This is a 369.61 percent increase over losses of $(1.02) per share from the same period last year.  The company reported quarterly sales of $542.71 million which beat the analyst consensus estimate of $29.91 million by 1.71K percent.</p>


ARWR

Arrowhead Pharma Q2 EPS $2.75 Beats $(0.16) Estimate, Sales $542.71M Beat $29.91M Estimate

<p>Vuzix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VUZI#NASDAQ">VUZI</a>) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 31.25 percent increase over losses of $(0.16) per share from the same period last year.  The company reported quarterly sales of $1.58 million which beat the analyst consensus estimate of $1.34 million by 18.34 percent.  This is a 21.11 percent decrease over sales of $2.00 million the same period last year.</p>


VUZI

Vuzix Q1 EPS $(0.11) Beats $(0.12) Estimate, Sales $1.58M Beat $1.34M Estimate

<p>Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.19) by 10.53 percent. This is a 54.35 percent increase over losses of $(0.46) per share from the same period last year.  The company reported quarterly sales of $133.67 million which beat the analyst consensus estimate of $132.16 million by 1.15 percent.  This is a 11.15 percent increase over sales of $120.26 million the same period last year.</p>


Plug Power Q1 EPS $(0.21) Misses $(0.19) Estimate, Sales $133.67M Beat $132.16M Estimate

<p>Quanterix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.44) by 20.45 percent. This is a 103.85 percent decrease over losses of $(0.26) per share from the same period last year.  The company reported quarterly sales of $30.33 million which beat the analyst consensus estimate of $28.20 million by 7.55 percent.  This is a 5.40 percent decrease over sales of $32.07 million the same period last year.</p>


Quanterix Q1 EPS $(0.53) Misses $(0.44) Estimate, Sales $30.33M Beat $28.20M Estimate

<p>Power Integrations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWI#NASDAQ">POWI</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.28 by 10.71 percent. This is a 72.22 percent increase over earnings of $0.18 per share from the same period last year.  The company reported quarterly sales of $105.53 million which beat the analyst consensus estimate of $105.37 million by 0.15 percent.  This is a 15.10 percent increase over sales of $91.69 million the same period last year.</p>


POWI

Power Integrations Q1 Adj. EPS $0.31 Beats $0.28 Estimate, Sales $105.53M Beat $105.37M Estimate

<p>Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) reported quarterly losses of $(0.83) per share which beat the analyst consensus estimate of $(0.92) by 9.78 percent. This is a 33.87 percent decrease over losses of $(0.62) per share from the same period last year.  The company reported quarterly sales of $7.50 million which beat the analyst consensus estimate of $1.11 million by 577.42 percent.</p>


XENE

Xenon Pharmaceuticals Q1 EPS $(0.83) Beats $(0.92) Estimate, Sales $7.50M Beat $1.11M Estimate

<p>Today FOX Advertising announces the launch of the&nbsp;OneFOX converged media platform, powered by AdRise built on a foundation of AI-driven technology and tools.</p>
<p>This intelligence platform will harness audience &amp; contextual signals along with behavioral, creative and campaign analytics to create more personalized ad experiences for consumers and increase ad efficacy for advertisers.</p>
<p>The genesis of the platform began a little over a year ago with AdRise developing the proprietary building blocks that support unified planning tools, activation and measurement across FOX Entertainment, FOX Sports, FOX News Media and Tubi.</p>
<p>The accelerated growth and evolution of machine learning and LLMs, has unlocked new entrants into the category and with FOX's investment, AdRise has been at the forefront in building next gen capabilities to better connect fans and brands. These solutions are underpinned by a data strategy that moves from an over-reliance on identities to AI-driven matches and inferences focused on outcomes. This strategy will also evolve clean-rooms and retail media networks towards true secure data co-ops.</p>
<p>"There is a lot of buzz about AI, but we're actually seeing a growing number of partners and customers experiment with AI-driven audience modeling and advanced targeting that will dramatically enhance current identity-based infrastructures," said Stephano Kim, Chief Strategy and Operations Officer, FOX Ad Sales. "As we lean into protecting consumer data and their privacy, we are looking for better alternatives to connecting brands and their consumers in a safe and compliant way."</p>
<p>OneFOX has been building towards a unified solution for the last few years and this Upfront season will culminate in a platform release that enables marketers to activate FOX's portfolio with precision across its premium live, on-demand and digital content. This proprietary intelligence platform will dynamically align brand goals with the right audience, programming, and consumer touch point to make every moment count for advertisers and FOX's audiences.&nbsp;</p>
<p>"OneFOX is known for delivering valuable and incremental audiences from across our portfolio of best-in-class content," said Jeff Collins, President of FOX Ad Sales, Marketing &amp; Brand Partnerships. "We've heavily invested in these next gen solutions so that advertisers can now maximize the impact they have when engaging with our leaned–in audience."</p>
<p>Key capabilities include:</p>
<ul>
<li>AI-Powered Planning: Predictive models surface optimal campaign strategies across genres and platforms—&nbsp;from the big game to breaking news.<br /><br /><br /><br />&nbsp;</li>
<li>Unified Activation: Converged audience insights enable holistic planning to be activated across linear, addressable and digital media.<br /><br /><br /><br />&nbsp;</li>
<li>Outcome-Based Measurement: Real-time insights tie media strategies to business outcomes and client objectives, including sales lift, engagement, and brand resonance.</li>
</ul>


FOXA

FOX Announces Launce Of AI-Driven Converged Media Platform Across Its Portfolio

<p>Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.38) by 10.53 percent. This is a 23.53 percent decrease over losses of $(0.34) per share from the same period last year.</p>


NMRA

Neumora Therapeutics Q1 EPS $(0.42) Misses $(0.38) Estimate

<p>Stagwell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STGW#NASDAQ">STGW</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $9.33, a high estimate of $10.00, and a low estimate of $8.00. Observing a 0.54% increase, the current average has risen from the previous average price target of $9.28. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747080104_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The standing of Stagwell among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Cahall</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Mark Zgutowicz</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Hold</td>
<td>$9.50</td>
<td>$9.50</td>
</tr>
<tr>
<td>Mark Zgutowicz</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$9.50</td>
<td>$10.00</td>
</tr>
<tr>
<td>Mark Zgutowicz</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$9.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$10.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Steven Cahall</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$9.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Stagwell. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Stagwell compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Stagwell's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Stagwell's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/STGW/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Stagwell analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Stagwell</h2>
<p>Stagwell Inc is the challenger holding company built to transform marketing. It delivers scaled creative performance for the world's ambitious brands, connecting culture-moving creativity with a technology to harmonize the art and science of marketing. The company's segments include Integrated Agencies Network; Brand Performance Network; and Communications Network. It generates maximum revenue from the Integrated Agencies Network segment. Geographically, it derives a majority of its revenue from the United States.</p>
<h3>Stagwell: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Decline in Revenue:</strong> Over the 3M period, Stagwell faced challenges, resulting in a decline of approximately <strong>-2.73%</strong> in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Communication Services sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-0.45%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Stagwell's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-0.88%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Stagwell's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-0.07%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>5.22</strong>, Stagwell faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

STGW

Expert Outlook: Stagwell Through The Eyes Of 9 Analysts

<p>5 analysts have expressed a variety of opinions on Aeva Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NASDAQ">AEVA</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $8.14, a high estimate of $11.00, and a low estimate of $5.22. Marking an increase of 54.46%, the current average surpasses the previous average price target of $5.27. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747080071_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The standing of Aeva Technologies among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>$5.22</td>
</tr>
<tr>
<td>Colin Rusch</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$9.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Announces</td>
<td>Buy</td>
<td>$9.50</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$5.22</td>
<td>$4.87</td>
</tr>
<tr>
<td>Colin Rusch</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$6.00</td>
<td>$5.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Aeva Technologies. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Aeva Technologies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Aeva Technologies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Aeva Technologies's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AEVA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Aeva Technologies analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Aeva Technologies</h2>
<p>Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.</p>
<h3>Unraveling the Financial Story of Aeva Technologies</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Aeva Technologies's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>67.35%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Aeva Technologies's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-1340.73%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-31.62%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Aeva Technologies's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-22.83%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.04</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AEVA

The Analyst Verdict: Aeva Technologies In The Eyes Of 5 Experts

Press Releases

Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference

Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences

Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

Comments

Tango Therapeutics

Noticias

Últimas noticias sobre Tango Therapeutics (NASDAQ:TNGX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL